Boston Scientific Expands Healthcare Impact with Strategic Acquisitions and Innovations in 2024

Boston Scientific has been actively advancing its portfolio and expanding its impact in the healthcare sector. On June 18, 2024, Boston Scientific announced its agreement to acquire Silk Road Medical for $1.16 billion. Silk Road Medical is known for its innovative TCAR procedure that reduces stroke risk in patients with carotid artery disease. The acquisition is expected to close in the latter half of 2024, with Silk Road Medical anticipating a 10-12% revenue growth for the year.

On May 18, 2024, Boston Scientific shared positive six-month results from the MODULAR ATP clinical trial of the mCRM™ System, which includes the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker (LP). The trial demonstrated high communication success and a significant complication-free rate, highlighting the potential for less invasive therapies for preventing sudden cardiac death. 

On May 8, 2024, Dr. Cheryl Pegus, with over 25 years of clinical and business leadership experience, was elected to Boston Scientific's board of directors. This appointment brings extensive expertise in healthcare innovation and expanding access to care to the board.

Boston Scientific reported strong financial results for the first quarter of 2024 on April 24, with net sales reaching $3.856 billion, a 13.8% increase year-over-year. Growth was driven by a diversified business portfolio and the launch of the FARAPULSE™ Pulsed Field Ablation System. Other key developments included FDA approvals for the AGENT™ Drug-Coated Balloon and the WATCHMAN TruSteer™ Access System.

On April 8, 2024, Boston Scientific initiated the NAVIGATE-PF study to evaluate the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module, aiming to improve guidance, reduce fluoroscopy times, and enhance patient outcomes in treating atrial fibrillation.

March 1, 2024, marked the FDA approval of the AGENT™ Drug-Coated Balloon for treating coronary in-stent restenosis, a significant advancement for patients with coronary artery disease. The approval was based on positive results from the AGENT IDE trial.

Boston Scientific completed a €2.0 billion offering of Senior Notes on February 27, 2024, to finance the acquisition of Axonics Inc. and repay existing senior notes. This follows the FDA's approval on February 6, 2024, for an expanded indication of the WaveWriter™ Spinal Cord Stimulator Systems to treat chronic low back and leg pain in patients without prior back surgery.

On January 31, 2024, Boston Scientific reported fourth-quarter 2023 net sales of $3.725 billion, marking a 14.9% increase from the previous year. The company also received FDA approval for its FARAPULSE™ Pulsed Field Ablation System for treating atrial fibrillation.

Throughout January 2024, Boston Scientific presented key data at the North American Neuromodulation Society Meeting, demonstrating the effectiveness of the WaveWriter Alpha™ Spinal Cord Stimulation Systems in providing sustained pain relief for non-surgical back pain. Additionally, on January 8, 2024, Boston Scientific announced its agreement to acquire Axonics Inc. for approximately $3.7 billion, aiming to expand its urology portfolio into high-growth areas.